全球静脉注射免疫球蛋白市场规模、份额、趋势和成长分析报告（2026-2034年）

预计静脉注射免疫球蛋白市场将从 2025 年的 129 亿美元成长到 2034 年的 249.2 亿美元，2026 年至 2034 年的复合年增长率为 7.59%。

由于治疗免疫力缺乏和自体免疫疾病的需求不断增长，全球静脉注射免疫球蛋白市场经历了显着增长。静脉注射免疫球蛋白是一种血液衍生治疗方法，用于增强免疫系统和治疗多种疾病。其对原发性免疫力缺乏缺陷症和神经系统疾病等疾病的疗效促进了其广泛应用。

关键驱动因素包括免疫相关疾病盛行率的上升以及人们对先进治疗方法的认识不断提高。医疗专业人员越来越依赖静脉注射免疫球蛋白疗法来治疗复杂疾病并改善患者预后。此外，血浆采集和纯化技术的进步正在扩大产能并提高治疗的可及性。

随着免疫相关疾病研究的不断深入，静脉注射免疫球蛋白市场预计将持续成长。医疗基础设施的扩张和诊断能力的提升可能会增加治疗需求。血浆衍生疗法的持续创新和临床应用的不断拓展，有望支撑该市场的长期发展。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球静脉注射免疫球蛋白市场：依应用领域划分

• 市场分析、洞察与预测
• 免疫不全症
• CIDP
• 低丙种球蛋白血症
• 先天性爱滋病
• 慢性淋巴性白血病
• 重症肌无力
• 多灶性运动神经病变
• ITP
• 川崎病
• Guillain-Barré二氏症候群
• 其他的

第五章：全球静脉注射免疫球蛋白市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 专科药房
• 其他的

第六章 全球静脉注射免疫球蛋白市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Biotest AG
  • Baxter
  • Octapharma AG
  • LFB
  • Grifols SA
  • CSL
  • China Biologics Products Inc
  • Kedrion
  • BDI Pharma Inc

The Intravenous Immunoglobulin Market size is expected to reach USD 24.92 Billion in 2034 from USD 12.90 Billion (2025) growing at a CAGR of 7.59% during 2026-2034.

The global intravenous immunoglobulin market has experienced substantial growth due to increasing demand for therapies that treat immune deficiencies and autoimmune diseases. Intravenous immunoglobulin is a blood-derived therapy used to strengthen the immune system and manage various medical conditions. Its effectiveness in treating disorders such as primary immunodeficiency and neurological diseases has contributed to widespread adoption.

Key drivers include rising prevalence of immune-related disorders and growing awareness of advanced treatment options. Healthcare providers increasingly rely on intravenous immunoglobulin therapy to manage complex conditions and improve patient outcomes. Additionally, advancements in plasma collection and purification technologies have helped expand production capacity and improve treatment availability.

Looking ahead, the intravenous immunoglobulin market is expected to grow as research into immune-related diseases continues to advance. Expanding healthcare infrastructure and improved diagnostic capabilities may increase treatment demand. Ongoing innovation in plasma-derived therapies and expanding clinical applications are likely to support the long-term development of this market.

MARKET SEGMENTATION

By Application

• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Other

COMPANIES PROFILED

• Biotest AG, Baxter, Octapharma AG, LFB, Grifols SA, CSL, China Biologics Products Inc, Kedrion, BDI Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Immunodeficiency diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CIDP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hypogammaglobulinemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Congenital AIDS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chronic Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Myasthenia Gravis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Multifocal motor neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. ITP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Kawasaki disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Guillain-Barre syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Biotest AG
  • 8.2.2 Baxter
  • 8.2.3 Octapharma AG
  • 8.2.4 LFB
  • 8.2.5 Grifols SA
  • 8.2.6 CSL
  • 8.2.7 China Biologics Products Inc
  • 8.2.8 Kedrion
  • 8.2.9 BDI Pharma Inc